Oxford Biomedica’s (OXB) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Oxford Biomedica (LON:OXB) in a research report report published on Tuesday morning, Marketbeat Ratings reports. They currently have a GBX 740 ($9.41) price objective on the biopharmaceutical company’s stock.

Separately, Numis Securities restated a hold rating and set a GBX 180 ($2.29) target price on shares of Oxford Biomedica in a report on Wednesday, March 20th.

Oxford Biomedica Stock Performance

LON:OXB opened at GBX 331.50 ($4.21) on Tuesday. The company has a current ratio of 3.32, a quick ratio of 1.67 and a debt-to-equity ratio of 57.10. The firm has a market capitalization of £331.50 million, a price-to-earnings ratio of -517.97 and a beta of 1.03. The firm’s fifty day simple moving average is GBX 239.49 and its 200 day simple moving average is GBX 206.95. Oxford Biomedica has a twelve month low of GBX 164.29 ($2.09) and a twelve month high of GBX 474.50 ($6.03).

About Oxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.